Pancreatic cancer: genetics, disease progression, therapeutic resistance and treatment strategies  

作　　者：Karnika Singh Gauri Shishodia Hari K.Koul 

机构地区：[1]Department of Radiation Oncology,The Ohio State University Comprehensive Cancer Center,Columbus,OH 43210,USA [2]Department of Otolaryngology/Head&Neck Cancer Surgery,LSU Health Sciences Center,Shreveport,LA 71103,USA [3]Department of Biochemistry&Molecular Biology,Urology and Stanley S Scott Cancer Center School of Medicine LSU Health Sciences Center,New Orleans,LA 70112,USA.

出　　处：《Journal of Cancer Metastasis and Treatment》2021年第1期794-808,共15页癌症转移与治疗（英文版）

基　　金：supported in part by funds from Carroll W.Feist Endowed Chair in Cancer(Koul HK);LSUHSC-graduate stipend to Singh K.Koul HK is supported in part by the NIH/NCI RO1 R01CA242839.

摘　　要：Pancreatic cancer is a deadly disease and the third-highest cause of cancer-related deaths in the United States.It has a very low five-year survival rate(<5%)in the United States as well as in the world(about 9%).The current gemcitabine-based therapy soon becomes ineffective because treatment resistance and surgical resection also provides only selective benefit.Signature mutations in pancreatic cancer confer chemoresistance by deregulating the cell cycle and promoting anti-apoptotic mechanisms.The stroma-rich tumor microenvironment impairs drug delivery and promotes tumor-specific immune escape.All these factors render the current treatment incompetent and prompt an urgent need for new,improved therapy.In this review,we have discussed the genetics of pancreatic cancer and its role in tumor evolution and treatment resistance.We have also evaluated new treatment strategies for pancreatic cancer,like targeted therapy and immunotherapy.

关 键 词：Pancreatic cancer signature mutations GEMCITABINE DESMOPLASIA therapeutic resistance IMMUNOTHERAPY 

分 类 号：R73[医药卫生—肿瘤]